West Pharmaceutical stock (US9523901012): Geode Capital steps up buying as analyst consensus holds at Moderate Buy

West Pharmaceutical shares on the NYSE remain near recent highs while Geode Capital Management has disclosed an increased position and analysts keep a Moderate Buy consensus with an average 12-month price target around USD 324 per share.

West Pharmaceutical shares continue to trade close to recent highs on the New York Stock Exchange, as institutional investors add to positions and Wall Street research houses maintain a broadly constructive stance on the United States-based healthcare supplier.

According to NYSE data cited by several market services, the stock last closed at USD 322.81 on 05/29/2026, placing West Pharmaceutical near the upper end of its 12-month trading range and implying a market capitalization in the multi-billion dollar bracket for the Pennsylvania-headquartered group.

A recent filing summarized by MarketBeat indicates that Geode Capital Management has acquired 11,962 additional shares of West Pharmaceutical, underscoring continuing institutional interest in the company as it executes its capital allocation framework.

Alongside this ownership move, West Pharmaceutical's board has authorized a USD 1 billion share repurchase program, providing another lever to return capital to shareholders and potentially support earnings per share over time if executed against stable or rising cash flows.

On the home market in the United States, the stock trades under the ticker WST on the NYSE, and investors often monitor it as part of the broader health care and life sciences tools and services segment rather than as a diversified pharmaceutical group.

For German-speaking investors, West Pharmaceutical is also accessible on electronic venues such as Tradegate via secondary listings, typically quoted in euro and tracking the NYSE line with currency adjustments, though liquidity and spreads differ from the primary market.

The disclosed Geode Capital purchase and the continuing buyback authorization serve as the main current triggers for the stock, complementing the analyst backdrop and offering an updated view of how both management and large institutions are positioning around West Pharmaceutical at the start of June 2026.

The stock traded at USD 322.81 on 05/29/2026 on the New York Stock Exchange, according to NYSE data as of 05/29/2026, with recent volumes broadly in line with historical averages.

As of: 06/01/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: West Pharmaceutical
• Sector/industry: Healthcare equipment and contract pharmaceutical packaging
• Headquarters/country: Exton, United States
• Core markets: North America, Europe and selected Asia-Pacific healthcare and pharma hubs
• Key revenue drivers: Injectable drug packaging components, delivery systems and related services for biopharma customers
• Home exchange/listing venue: New York Stock Exchange (WST)
• Trading currency: USD

West Pharmaceutical: core business model

West Pharmaceutical focuses on supplying specialized containment and delivery solutions for injectable medicines, with revenue primarily generated from selling high-value components and services to global pharmaceutical and biotech companies.

What banks and research houses say about West Pharmaceutical

On the analyst side, data compiled by MarketBeat as of 05/29/2026 show that 12 Wall Street equity research analysts cover West Pharmaceutical, with a consensus rating described as Moderate Buy based on their latest recommendations.

Across these 12 analysts, the average 12-month price target stands at USD 324.00 per share, with individual published targets ranging from USD 295.00 on the low end to USD 350.00 on the high end, implying only a modest upside of around 0.37 percent from the 05/29/2026 closing price of USD 322.81 on the NYSE.

According to MarketBeat as of 05/29/2026, this Moderate Buy consensus reflects a mix of Buy and Hold ratings from large brokerages and research houses following the stock, with no universally agreed high-conviction view but a broadly positive stance on the company’s fundamentals.

The relatively tight range between the average target of USD 324.00 and the current share price close to USD 323.00 suggests that, in aggregate, analysts see West Pharmaceutical as fairly valued to slightly above-neutral in the near term, while still acknowledging its strategic role in supplying critical components to pharmaceutical manufacturers.

Conclusion

Geode Capital Management’s latest purchase of West Pharmaceutical shares and the USD 1 billion share repurchase authorization highlight how both institutional investors and the company’s board are engaging with the stock at current valuation levels.

At the same time, the wall of sell-side research summarized by MarketBeat indicates a Moderate Buy consensus with an average price target of USD 324.00 per share, signaling that analysts see incremental but not dramatic upside from the recent NYSE close around USD 322.81 as of 05/29/2026.

For investors following the US healthcare tools and packaging space, the combination of active capital returns, institutional ownership trends and a relatively balanced analyst stance offers a structured framework for monitoring how West Pharmaceutical’s share price responds to future earnings releases and sector developments.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.